Status:

UNKNOWN

Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention

Lead Sponsor:

J.P.S Henriques

Conditions:

Atrial Fibrillation

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Rationale: Patients with atrial fibrillation who undergo percutaneous coronary intervention for coronary artery disease are treated with antiplatelet therapy on top of a non-vitamin K oral anticoagula...

Eligibility Criteria

Inclusion

  • Age ≥18 years
  • Successful PCI
  • History of or newly diagnosed (\<72 hours after PCI/ACS) AF or atrial flutter with a long-term (≥ 1 year) indication for OAC
  • Treatment with a loading dose of clopidogrel and aspirin prior to or during PCI

Exclusion

  • Known allergy or contraindication for rivaroxaban
  • Current indication for OAC besides atrial fibrillation/flutter (e.g. venous thromboembolism)
  • Overwriting indication for DAPT (e.g. TIA/CVA or PAD)
  • Mechanical heart valve prosthesis
  • Moderate to severe mitral valve stenosis (AVA ≤1.5 cm2)
  • Intracardiac thrombus or apical aneurysm requiring OAC
  • Kidney failure (eGFR \<15)
  • Active liver disease (ALT, ASP, AP \>3x ULN or active hepatitis A, B or C)
  • Active malignancy excluding non-melanoma skin cancer
  • Active bleeding on randomization
  • Severe anaemia requiring blood transfusion
  • Pregnancy or breast-feeding women
  • Planned high-bleeding risk surgical intervention within 6 months after PCI for stable CAD and 12 months after PCI for ACS
  • PCI of left main disease, chronic total occlusion, bifurcation lesion requiring two-stent treatment, saphenous or arterial graft lesion, severely calcified lesions
  • Participation in another trial with an investigational drug or device (i.e. stent)

Key Trial Info

Start Date :

January 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06103266

Start Date

January 1 2024

End Date

December 1 2025

Last Update

October 26 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Rivaroxaban Monotherapy After CYP2C19 Genotype Testing in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention | DecenTrialz